Supported in part by National Institutes of Health/National Eye Institute Grants EY021818 (FAM), EY11008 (LMZ), EY14267 (LMZ), EY019869 (LMZ), Core Grant P30EY022589; an unrestricted grant from Research to Prevent Blindness (New York, NY, USA); grants for participants' glaucoma medications from Alcon, Allergan, Pfizer, Merck, and Santen; and fellowships from Brazilian National Research Council-CAPES 12309-13-3 (CPBG).
Disclosure: C.P.B. Gracitelli, None; A.J. Tatham, Heidelberg Engineering (I); L.M. Zangwill, Carl Zeiss Meditec (I), Heidelberg Engineering (I), Nidek (I), Topcon (I); R.N. Weinreb, Aerie (I), Alcon (C), Allergan (C), Bausch & Lomb (C), Carl Zeiss Meditec (C, I), Genentech (I), Heidelberg Engineering (I), National Eye Institute (I), Nidek (I), Novartis (I), Optovue (I), Sensimed (C), Topcon (C, I); R.Y. Abe, None; A. Diniz-Filho, None; A. Paranhos Jr, None; S. Baig, None; F.A. Medeiros, Alcon Laboratories (I), Allergan (C, I), Bausch & Lomb (I), Carl Zeiss Meditec (C, I), Heidelberg Engineering (I), Merck (I), National Eye Institute (I), Novartis (C), Reichert (I), Sensimed (I), Topcon (I)